CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.
Peter Martin(Northwestern University), Bruce D. Cheson(National Cancer Institute), John P. Leonard(New York University), Kristy L. Richards(University of North Carolina at Chapel Hill), Kristie A. Blum(Emory University), Jeffrey L. Johnson(Henry Ford Health System), Nancy L. Bartlett(Washington University in St. Louis), Rebecca Elstrom(Acentech (United States)), Brandy Pitcher(Duke Medical Center), Sin‐Ho Jung(Duke University)
Cited by 40
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k